Immune escape remains a major barrier to durable cancer immunotherapy. Although checkpoint blockade has transformed cancer treatment, resistance commonly reflects broader tumor-intrinsic and microenvironmental programs that sustain immune dysfunction. At this interface, STAT3 emerges as a central organizing node. Beyond its canonical role in inflammatory and oncogenic signaling, STAT3 links tumor cell plasticity, immune suppression, and metabolic adaptation across the tumor ecosystem. In tumor cells, STAT3 promotes stemness, survival, checkpoint ligand expression, impaired antigen presentation, and immunosuppressive secretomes. In immune compartments, it drives regulatory T cell expansion, myeloid-derived suppressor cell accumulation, tumor-associated macrophage polarization, and dendritic cell dysfunction, thereby stabilizing an immune-resistant niche. STAT3 also reinforces immune escape through metabolic rewiring and multicellular feed-forward circuits. These features make STAT3 an attractive but challenging therapeutic target. Here, we discuss how STAT3 functions at the tumor-immune interface to coordinate immune escape and highlight therapeutic opportunities for targeting this axis in cancer.
Background. Cellular senescence is a negative prognostic indicator in glioblastoma (GB). However, the specific cell types exhibiting senescence and the molecular mechanisms by which senescent cells (SCs) contribute to GB pathogenesis remain unknown. Methods. We performed multi-omics integration of publicly available GB patient-derived datasets to identify SCs and their functional impact on GB pathogenesis. We created a transcriptomic definition of SCs to verify their presence in GB datasets. Next, we analyzed transcriptomic profiles of GB and low-grade gliomas to reveal key features of GB aggressiveness. The GB patients' phosphoproteome was analyzed with a focus on key regulators of senescence. To assess chemotherapy-evoked secondary senescence, we performed a proteomic analysis of temozolomide-induced senescence in human GB spheroids. Results. We identified GB-associated SCs in clusters radial glia, endothelial cells, and immature astrocytes localized primarily in the hypoxic zones. Notably, we identified senescence-escape features and tumor antiviral responses as processes distinguishing GB from low-grade gliomas. In GB samples, we detected inhibitory phosphorylation of p21 and p27 proteins and active PI3K signaling, which can lead to senescence escape and belong to the typical manipulation arsenal of herpesviruses. Our proteomic analysis of temozolomide-induced senescent GB cells reveals that primary (pre-radiochemotherapy) and secondary senescence in GB share similar phenotypic features. Pathways associated with GB aggressiveness are upregulated after therapy, which can promote more aggressive behavior of recurrent tumors. Conclusions. Our data indicate that senescence and viral reactivation may fuel GB progression, including recurrence, suggesting that senolytics and antiviral drugs are potential therapeutic avenues.
Object category learning is a foundational cognitive process. Most human category learning studies involve brief paradigms lasting a few hours and show increased shape tuning in visual areas and task-dependent responses in pFC. Other studies also identify a "frontal bottleneck" that limits multitasking. However, real-world categorization often involves months or years of practice, potentially producing qualitative shifts toward automaticity. We tested the hypothesis that extensive training causes a spatio-temporal shift in the neural circuitry supporting categorization. Participants were trained over >30,000 trials across 5-10 weeks to categorize novel morphed car stimuli via a mobile app. We used fMRI and EEG rapid adaptation techniques to examine neural responses after initial learning (∼4 hr in 1-2 weeks) and after extensive training (∼16 additional hours over another 4-8 weeks). Converging fMRI and EEG results showed that extensive training fundamentally remodeled task-related circuitry: Visual areas in ventral occipito-temporal cortex (vOTC) were initially shape-selective, but category-selective responses emerged in the vOTC after extensive training. The vOTC also showed decreased functional connectivity with the pFC and increased connectivity with motor output areas. This supports the hypothesis that extensive experience enables category decisions to occur outside of the "frontal bottleneck." Critically, the decrease in connectivity between vOTC and pFC was associated with improved categorization performance while dual-tasking, indicating increased automaticity. These findings demonstrate that prolonged training reshapes the neural basis of categorization, shifting it from a flexible but attentionally controlled process to a more streamlined, automatic process.
暂无摘要（点击查看详情）
The CKLF-like MARVEL transmembrane domain containing superfamily (CMTM) has an important role in tumour immunity. The role of CMTM8 in tumour immune microenvironment (TIME) remains unknown. The aim was to investigate the relationship between CMTM8 and antitumour immunity. Lentiviral system was established to achieve functional edition of CMTM8. CMTM8 in tumour progression and TIME was investigated by using subcutaneous xenograft mice tumour models. CMTM8 targeting was achieved using an adeno-associated virus (AAV)-based shRNA vector. Clinical data showed that high expression of CMTM8 in melanoma and colorectal cancer is associated with lower patient survival rates and poorer intra-tumoural immune cell infiltration. Mouse melanoma and colon cancer models, CMTM8 expression markedly accelerated tumour growth by regulating intra-tumoural infiltration of CD8+ T cells and NK cells. RNA sequencing of CMTM8-overexpressed B16 cells showed that Notch pathway is significantly up-regulated, and blockade of Notch pathway in vivo resulted in lower intra-tumoural infiltration of CD8+ T cells and NK cells, and confined tumour progression. CMTM8 could down-regulate the EGFR pathway by promoting endocytosis of EGFR, possible leading to higher expression of Notch1. Similar this observed in human colon cancer in a PBMC-engrafted NCG model. Besides, we developed the CMTM8-targeting adeno-associated virus, which effectively up-regulated intra-tumoural infiltration of CD8+ T cells and NK cells and inhibited tumour growth. Tumour-intrinsic CMTM8 could possibly regulate TIME via EGFR-Notch axis and that CMTM8 is a promising target for tumour immunotherapy, especially for treatment of colorectal cancer or melanoma patients.
暂无摘要（点击查看详情）
暂无摘要（点击查看详情）
Immune checkpoint blockade (ICB), including PD-1/PD-L1 inhibitors, has transformed cancer therapy but benefits only a subset of patients. Understanding how PD-L1 is regulated and identifying strategies to overcome resistance remain critical. Here, we identify SIRT2 as a key positive regulator of PD-L1 across multiple human cancers. Unexpectedly, SIRT2 does not act at the transcriptional level but stabilizes PD-L1 protein by preventing ubiquitin-mediated degradation. Mechanistically, SIRT2 maintains the protein stability of USP22, a PD-L1 deubiquitinase. Loss of SIRT2 reduces USP22 levels, whereas ectopic USP22 fully rescues PD-L1 expression and reverses the enhanced antitumor immunity induced by SIRT2 inhibition. We further show that SIRT2 directly deacetylates USP22 at lysines 382 and 505 within its catalytic domain, promoting USP22 deubiquitinase activity and protecting both itself and its substrates from degradation. Our findings reveal a molecular mechanism by which an acetylation-deacetylation switch dynamically regulates deubiquitinase catalytic activity. Therapeutically, SIRT2 inhibition synergizes with PD-1/PD-L1 blockade and USP22 inhibition to enhance antitumor immunity. Consistently, protein but not mRNA levels of SIRT2, USP22, and PD- L1 positively correlate in human bladder cancer and melanoma. Together, these findings define a SIRT2-USP22-PD-L1 axis driving tumor immune evasion and highlight SIRT2 as a promising target to improve ICB efficacy.
Sleep deprivation poses critical safety risks in high-stakes professions, where traditional stimulants often fail to sustain cognitive performance. Addressing the need for novel cognitive enhancers, this study compared the effects of modafinil and caffeine with novel nicotinic (AVL-3288) and glutamatergic (CX516) positive allosteric modulators on behavior and memory in severely sleep-deprived mice. Male C57BL/6 mice underwent 48 hours of paradoxical sleep deprivation before receiving intraperitoneal doses of modafinil (300 mg/kg), caffeine (10 mg/kg), AVL-3288 (1, 2 mg/kg), CX516 (40, 80 mg/kg), or vehicle. A behavioral test series assessed locomotor activity (Open Field), anxiety (Elevated Plus Maze), reward-based working and spatial memory (Eight-Arm Radial Maze), escape-based spatial memory (Barnes Maze), and depressive mood (Tail Suspension). Modafinil markedly increased locomotor activity and suppressed appetite. Caffeine, AVL-3288 (1 mg/kg), and CX516 (40 mg/kg) improved reward-based working memory (Eight- Arm Radial Maze). However, these same agents impaired performance in the escape-based spatial reference memory task (Barnes Maze). No mood-altering effects were observed. The novel modulators displayed complex, non-dose-dependent profiles. Under severe sleep deprivation, specific wakefulness-enhancing substances can yield contrasting outcomes, enhancing reward-associated memory while negatively affecting escape-associated memory. These divergent outcomes suggest that neuromodulation during severe sleep deprivation exerts task-dependent behavioral effects, though the precise mechanisms driving the differences between the two maze paradigms remain to be elucidated. Pharmacological interventions under severe sleep deprivation can produce complex, bidirectional effects on cognition. This highlights that cognitive enhancement is likely task-dependent rather than global, necessitating a comprehensive assessment of diverse behavioral domains.
This study proposes a three-dimensional path planning method for UAV swarms using the Multi-Strategy Improved Crested Porcupine Optimizer (ICPO), designed to enable UAVs to more effectively avoid obstacles and optimize flight paths. This study integrates tent mapping with the reverse refraction learning strategy to enhance the diversity of the algorithm's population. Inspired by animal escape behavior, the first defense strategy is replaced with a moving escape strategy to expand the global search. The fourth defense strategy is improved using a Cauchy distribution, making the probability distribution independent of the global optimal solution, thereby rendering the search process independent and flexible while reducing computational complexity. To avoid getting stuck in local optima later in the process, a Cauchy-Gaussian mutation strategy was introduced, enabling the algorithm to better escape local optima. Simulations were conducted on the 2005 and 2022 test sets, and the results demonstrated that ICPO exhibits superior robustness and stability. In 3D terrain simulations, the ICPO algorithm proved its effectiveness in path planning.
This review discusses recent advances in understanding the mechanisms of CNS HIV invasion and persistence and examines how these processes relate to the neurologic complications of HIV. Recent studies have provided compelling evidence that HIV can persist within CNS macrophages and microglia despite long-term suppressive ART, supporting the existence of a CNS reservoir. Updates to treatment of neurosymptomatic CSF HIV RNA escape include evaluation of CNS-specific drug resistance patterns and ART optimization. Evaluation of cognitive symtpoms in persons with HIV should include a comprehensive medical and neurologic evaluation, cessation of Efavirenz, and evaluation of HIV disease activity and immune dysregulation. Novel HIV cure strategies, including shock-and-kill approaches, block-and-lock strategies, and broadly neutralizing antibodies have highlighted the importance of understanding CNS reservoir dynamics and potential neurotoxicity when designing HIV cure strategies. HIV enters the CNS during early infection and may establish a persistent viral reservoir. CNS HIV persistence has important clinical implications, including symptomatic CSF HIV RNA escape and cognitive dysfunction, and may represent a barrier to HIV cure.
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high efficacy in clinical trials and early real-world studies. Although widespread resistance has not been reported, concerns remain about the emergence of escape variants, particularly among RSV-B viruses. During the 2024-25 RSV season in France, RSV-B predominated, providing a unique opportunity to examine breakthrough infections with RSV-B and resistance at a large scale. The study aimed to characterise RSV escape from nirsevimab using genotypic and phenotypic methods. This POLYRES-2 project was a multicentre, national, observational study conducted in hospital settings (inpatients and outpatients) across France during the 2024-25 RSV season. We included infants aged 1 year or under with a RT-PCR-confirmed RSV infection in routine care, regardless of whether they had received nirsevimab. Infants were identified through hospital virology laboratory databases. Each participating centre was requested to include a balanced number of nirsevimab-exposed and non-exposed infected infants throughout the study period. Clinical data were retrieved from electronic medical records. We compared RSV susceptibility to nirsevimab in infants who received nirsevimab with that in nirsevimab-naive infants. Respiratory samples were sequenced for full-length RSV genomes. To ensure reliability, phylogenetic and mutational analyses were restricted to high-quality sequences with greater than or equal to 90% genome coverage and complete reads across the nirsevimab-binding site. Clinical RSV isolates were tested for neutralisation by nirsevimab. We analysed F candidate substitutions using a fusion inhibition assay. The primary outcomes were presence of RASs in the RSV F protein (site Φ) and phenotypic resistance to nirsevimab. Among 1023 RSV-infected infants, 858 (83·9%) had full-length RSV genome sequences: 419 (48·8%) from nirsevimab-treated breakthrough infections (212 [50·6%] RSV-A, 207 [49·4%] RSV-B) and 439 (51·2%) from nirsevimab-naive infants (192 [43·7%] RSV-A, 247 [56·3%] RSV-B). RASs were identified in two of 195 RSV-A breakthrough infections (1·0%) and in 23 of 184 RSV-B breakthrough infections (12·5%). In RSV-A, the only RAS was F:K209E, conferring intermediate resistance. In RSV-B, resistance was more frequent and diverse than in RSV-A: 12 of 23 (52.2%) resistant viruses carried a substitution at residue 208 (F:N208D, F:N208I, F:N208K, F:N208S, or F:N208Y). Additional novel substitutions, including F:I64V/F:K65E, F:K68I, F:L204S, and F:P205S, also mediated resistance. Notably, a resistant RSV-B variant (F:N208S) was detected almost 1 year after prophylaxis. No resistant RSV was detected in nirsevimab-naive infants. Resistance to nirsevimab in RSV-B can emerge in real-world settings, affecting around 12% of breakthrough infections and showing greater diversity than previously recognised, although the clinical impact remains constrained by available evidence. Detection of resistant variants long after prophylaxis highlights the need for extended genomic surveillance. Integration of clinical and virological data will be essential to sustain the long-term effectiveness of RSV monoclonal antibody programmes. This study was supported by a grant from the Agence Nationale de Recherche sur le Sida et les hépatites virales - Maladies Infectieuses Emergentes and the French Ministry of Health and Prevention.
Dual-reactive T cell receptors (TCRs) that recognize the HIV-1 Gag TL9 epitope presented by both HLA-B*81:01 and HLA-B*42:01 are associated with improved immune control. However, whether such TCRs rely on a single universal recognition blueprint or adopt distinct structural solutions remains unclear. Here, we characterize 14D7, an additional dual-reactive TL9-specific TCR, and compare its structural features with those of the previously reported T18A clonotype. The 14D7-HLA-B*81:01-TL9 structure reveals a conserved non-canonical recognition framework shared with T18A: in both TCRs, CDR3β primarily engages the HLA α2 helix rather than the peptide, while CDR2β compensates via critical peptide contacts. However, 14D7 adopts a distinct CDR3 loop conformation, likely reflecting differences in V/J gene usage and junctional rearrangement, demonstrating that dual-reactive TCRs can achieve cross-reactivity through related but non-identical molecular solutions. AlphaFold 3 modeling further suggests that, like T18A, 14D7 actively remodels the TL9 conformation in the HLA-B*42:01 context toward a state resembling that observed in the HLA-B*81:01-bound complex. Surface plasmon resonance analysis revealed differential affinity profiles across HLA backgrounds, with greater tolerance to common escape variants in the HLA-B*81:01 context. Structural comparison further suggests that polymorphic HLA residues, particularly at positions 143 and 163, reshape the peptide- and TCR-facing interaction network and thereby influence tolerance to epitope variation. Together, these findings show that dual-reactive TCRs operate within a conserved non-canonical recognition framework while retaining flexibility at the level of CDR3 loop configuration, providing a refined structural basis for HIV-specific cross-reactive T cell immunity.
Human papillomavirus type 16 (HPV16) causes more cancer than any other virus. However, most HPV16 infections are controlled by the host's immune system and it remains unclear how viral and host genetic variation contribute to infection outcomes. Here, we analyze 4704 HPV16 whole genomes to identify 56 viral codons putatively under positive natural selection to change their amino acids, with evidence including dN/dS > 1, evolutionary convergence, and structural importance in the protein. We find that codons under positive selection disproportionately overlap known HPV16 immune epitopes recognized by cytotoxic T lymphocytes, particularly those restricted by the previously reported risk allele HLA-B*07:02 (odds ratio [OR] = 4.9; 95%CI = 2.1-10.3; PFisher = 0.00015), exemplified by position 10 of the E6 oncoprotein. Positively selected codons also disproportionately overlap 158 nucleotide sites at which the evolutionary sub/lineages of HPV16 have diverged (OR = 19.1; 95%CI = 10.5-34.7; PFisher < 2.2×10-16), and show more rare variation in cervical precancers/cancers than controls (benign or cleared HPV16 infections) in the E1 protein (OR = 9.34, 95%CI = 1.4-402.5; PFisher = 0.0084). Our results suggest that a small subset of HPV16 variants can improve viral persistence through escape of HLA-related immune recognition. The interaction of HPV16 and HLA variation may help to explain how similar or identical viral isolates can have such disparate infection outcomes.
Nanomaterials can shape antitumor immunity; however, the design rules that link molecular features to immune outcomes remain unclear. Here, we demonstrate that helical polypeptides with quaternary amine sidechains physically disrupt phospholipid membranes, triggering the release of damage-associated molecular patterns (DAMPs) and enabling cytosolic gene delivery. Screening various sidechain amines and using mechanistic assays with a racemic control identifies quaternary amines, along with helicity, as key factors in immune responses. Mechanistically, physical membrane disruption damages membrane-based organelles-including mitochondria, the endoplasmic reticulum, and endosomes-leading to immunogenic cell death and facilitating endosomal escape of nucleic acids. Guided by this mechanism, guanidinium substitution strengthened phosphate engagement and reduced the apparent cationic density, thereby improving polyplex stability and immune activation. In mouse models of melanoma and colon cancer, local transfection with a PD-L1 knockout plasmid using a helical polypeptide reduced tumor burden by 70-80% and boosted effector T cell-mediated immunity. These findings illustrate how sidechain chemistry and helicity affect immune activation, offering a non-viral platform for antitumor immune priming.
Substantially high morbidity and mortality rates are associated with antimicrobial resistance (AMR), which poses an alarming challenge to global healthcare. The causative, drug-resistant superbugs (headed by Staphylococcus aureus) adopt multiple strategies to escape the biocidal action of antibacterial drugs. This results in depleting the number of effective treatment alternatives and eventually leading to one of the nosocomial pathogens, Methicillin-resistant S. aureus (MRSA) related infections. Collectively, these concerns highlight a pressing urgency to replenish the drug discovery pipeline. In this context, we established an effective synthetic and screening platform to design and synthesize a series of C-3 alkylated indole derivatives. The biological assessment of the synthesized analogs identified potential hit molecules 9k and 11b with decent antimicrobial activity against the MRSA pathogen. Leveraging these initial hits, we re-designed and synthesized 2nd generation series of their analogues, through a strategic structural modification approach to further optimize their biological potential. Their antibacterial evaluation led to the identification of two aniline/amine-based potent hit molecules, 14f and 14l, with MIC values of 5.89 μM and 6.02 μM, respectively, against the MRSA pathogen. These hits presented a high safety profile with effective killing kinetics and anti-biofilm properties. The potent hits 14f and 14l exhibited membrane-targeting nature as confirmed through cell integrity and membrane permeability studies, and were also found to elicit secondary cellular responses such as oxidative stress generation and ATP depletion, leading to cell death. Thus, the present study lays the groundwork for the development of novel indole-based antibacterial scaffolds against MRSA.
Colorectal cancer (CRC) is a highly prevalent malignant tumor of the digestive tract worldwide, with significant regional variations in its epidemiological characteristics. Traditional treatments including surgery, chemotherapy, and radiotherapy have limited efficacy and substantial adverse events, which can no longer meet clinical needs. In recent years, immunotherapy has brought new breakthroughs for CRC by reshaping the tumor microenvironment (TME) and blocking tumor immune escape. This review systematically summarizes the core mechanisms and clinical applications of major immunotherapies such as immune checkpoint inhibitors (ICIs) and oncolytic viruses (OVs). We focus on individualized treatment selection for different molecular subtypes (pMMR/MSS vs. dMMR/MSI-H), biomarker screening, efficacy evaluation, drug resistance mechanisms, and countermeasures. We also discuss novel targets and biomarker optimization for precision therapy. In addition, given the unique immune-related adverse events, we introduce the CRC "SSEIE" nursing model and its value in whole-process management. This review integrates the latest advances in CRC immunotherapy and nursing interventions, providing a reference for optimizing clinical regimens, improving nursing quality, and enhancing patient prognosis.
Insects inhabit complex vibroscapes shaped by substrate-borne vibrations from multiple biotic and abiotic sources. One underappreciated topic is how vibrations function in predator-prey interactions. Tiny warty birch caterpillars (Falcaria bilineata) are known to produce complex vibratory signals to defend leaf-tip territories against conspecifics, raising the question of whether vibratory signalling and sensing also play roles in predator-prey interactions. We staged encounters between resident neonate caterpillars and three natural intruders: conspecifics, ladybird beetle larvae and adult ladybird beetles, while simultaneously recording behaviour and substrate-borne vibrations. Resident caterpillars showed three key responses - vibratory signalling, freezing and dropping - but these responses varied strongly with intruder identity and stage of encounter. Residents signalled vigorously toward conspecifics, with rates escalating as intruders approached their territories. In contrast, encounters with predators evoked predator-specific defensive strategies including freezing and dropping. Adult ladybird beetles, which caused high mortality (43%), elicited rapid escape responses and subsequent territory abandonment, while ladybird beetle larvae, which caused no mortality, triggered slower responses with initial signalling that ceased upon closer approach. Critically, vibrations generated by the 'footsteps' of each approaching intruder type produced distinct vibratory 'signatures', differing in amplitude, spectral and temporal characteristics. Resident caterpillars also initiated defensive responses before physical contact, often when intruders were still centimetres away. Together, these findings demonstrate that these miniature larvae, no larger than ∼1-2 mm, thrive in complex vibroscapes where vibrations not only function to advertise territory ownership against conspecifics but also provide essential early-warning cues enabling sophisticated threat assessment and context-appropriate defensive responses in predator-rich environments.
Objective: The systematic evaluation of expansive genomic databases facilitates the discovery of clinically vital biomarkers. While Sideroflexin 3 (SFXN3) consistently displays elevated expression in head and neck squamous cell carcinoma (HNSCC), its specific pathobiological functions and prognostic value remain insufficiently characterized. This study aims to delineate the clinical and functional significance of SFXN3 in HNSCC. Methods: We interrogated SFXN3 expression patterns, patient survival outcomes, and immune cell infiltration characteristics utilizing multiple independent repositories, including the cancer genome atlas (TCGA) and gene expression omnibus (GEO). The prognostic independence of SFXN3 was verified via multivariate Cox regression. These computational findings were subsequently corroborated through targeted in vitro functional assays. Results: SFXN3 expression was significantly augmented in HNSCC, demonstrating strong correlations with advanced disease stages and reduced overall survival. Multivariate models confirmed its status as an independent prognostic indicator. Furthermore, SFXN3 upregulation was closely tied to an immunosuppressive microenvironment. In vitro validations revealed that SFXN3 knockdown substantially impairs cell proliferation while simultaneously sensitizing HNSCC cells to cisplatin-induced apoptosis via intrinsic pathways. Conclusion: Ultimately, SFXN3 represents a robust prognostic indicator and an actionable therapeutic vulnerability to counteract both drug resistance and tumor immune escape in HNSCC.
Acral lentiginous melanoma (ALM) is characterized by a low mutational burden, frequent chromosomal rearrangements, and profound epigenetic dysregulation, distinguishing it from ultraviolet (UV)-induced melanoma. Among the epigenetic regulators, Enhancer of Zeste Homolog 2 (EZH2), the catalytic component of the Polycomb Repressive Complex 2 (PRC2), plays a central role in chromatin compaction and transcriptional repression through trimethylation of histone H3 on lysine 27 (H3K27me3). EZH2 overexpression or hyperactivation contributes to tumor progression, immune evasion, and therapeutic resistance. Recent multi-omic studies have highlighted the importance of EZH2 in regulating melanoma plasticity, immune modulation, and metabolic reprogramming. In ALM, where canonical oncogenic mutations such as BRAF V600E and NRAS Q61 are less frequent, EZH2-driven epigenetic mechanisms may play an even more dominant role in tumor initiation and progression. Pharmacological inhibitors of EZH2, including tazemetostat, have shown promise in preclinical melanoma models by restoring antigen presentation, enhancing CD8+ T-cell infiltration, and reversing transcriptional programs associated with immune resistance. This review aims to summarize the role of EZH2 in the molecular pathogenesis of ALM, emphasizing its contributions to epigenetic regulation, tumor plasticity, and immune escape, and discusses emerging therapeutic strategies targeting EZH2-mediated pathways to improve outcomes for this aggressive melanoma subtype.